Literature DB >> 18673121

NS5A--from obscurity to new target for HCV therapy.

Uli Schmitz1, Seng-Lai Tan.   

Abstract

The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18673121     DOI: 10.2174/157489108784746597

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  23 in total

1.  Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.

Authors:  Angela M Lam; Christine Espiritu; Shalini Bansal; Holly M Micolochick Steuer; Veronique Zennou; Michael J Otto; Phillip A Furman
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 2.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

Review 3.  High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay.

Authors:  Sandeep Amberkar; Narsis A Kiani; Ralf Bartenschlager; Gualtiero Alvisi; Lars Kaderali
Journal:  World J Virol       Date:  2013-05-12

4.  Clustering of rare peptide segments in the HCV immunome.

Authors:  Angela Stufano; Giovanni Capone; Barbara Pesetti; Lorenzo Polimeno; Darja Kanduc
Journal:  Self Nonself       Date:  2010-02-03

Review 5.  New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.

Authors:  Jing Tong; You-wei Wang; Yuan-an Lu
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

6.  Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

Authors:  Simon Giroux; Jinwang Xu; T Jagadeeswar Reddy; Mark Morris; Kevin M Cottrell; Caroline Cadilhac; James A Henderson; Oliver Nicolas; Darius Bilimoria; Francois Denis; Nagraj Mani; Nigel Ewing; Rebecca Shawgo; Lucille L'Heureux; Subajini Selliah; Laval Chan; Nathalie Chauret; Francoise Berlioz-Seux; Mark N Namchuk; Anne-Laure Grillot; Youssef L Bennani; Sanjoy K Das; John P Maxwell
Journal:  ACS Med Chem Lett       Date:  2013-01-27       Impact factor: 4.345

7.  Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

Authors:  Jeffrey L Romine; Denis R St Laurent; John E Leet; Scott W Martin; Michael H Serrano-Wu; Fukang Yang; Min Gao; Donald R O'Boyle; Julie A Lemm; Jin-Hua Sun; Peter T Nower; Xiaohua Stella Huang; Milind S Deshpande; Nicholas A Meanwell; Lawrence B Snyder
Journal:  ACS Med Chem Lett       Date:  2011-01-11       Impact factor: 4.345

Review 8.  Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Authors:  Abhik Saha; Rajeev Kaul; Masanao Murakami; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

9.  TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

Authors:  D G Cordek; J T Bechtel; A T Maynard; W M Kazmierski; C E Cameron
Journal:  Drugs Future       Date:  2011-09       Impact factor: 0.148

Review 10.  Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression.

Authors:  Concetta Panebianco; Chiara Saracino; Valerio Pazienza
Journal:  Tumour Biol       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.